Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells

被引：0
|
作者：
Kong, A. [1 ]
Calleja, V. [1 ]
Leboucher, P. [2 ]
Harris, A. [3 ]
Parker, P. [4 ]
Larijani, B. [1 ]
机构：
[1] Canc Res UK, Cell Biophys Lab, London, England
[2] Coll France, F-75231 Paris, France
[3] Canc Res UK Mol Oncol, Weatherall Inst Mol Med, Oxford, England
[4] Canc Res UK, Prot Phosphorylat Lab, London, England
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72419-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：155 / 155
页数：1
相关论文
共 50 条
  • [1] Activation of alternative HER receptors mediates resistance to EGFR tyrosine kinase inhibitors in breast cancer cells
    Kong, A.
    Calleja, V.
    Leboucher, P.
    Harris, A.
    Parker, P.
    Larijani, B.
    EJC SUPPLEMENTS, 2008, 6 (09): : 9 - 9
  • [2] HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
    Kong, Anthony
    Calleja, Veronique
    Leboucher, Pierre
    Harris, Adrian
    Parker, Peter J.
    Larijani, Banafshe
    PLOS ONE, 2008, 3 (08):
  • [3] Mechanisms of resistance to EGFR tyrosine kinase inhibitors involving HER-family ligands and receptors
    Iwanaga, Kentaro
    Sueoka-Aragane, Naoko
    Sato, Akemi
    Nakamura, Tomomi
    Kobayashi, Naomi
    Sueoka, Eisaburo
    Kimura, Shinya
    CANCER RESEARCH, 2012, 72
  • [4] MicroRNA-21 Mediates Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
    Zhang, W. C.
    Slack, F. J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (08) : S1536 - S1536
  • [5] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Prasad Sanjay Dhiwar
    Gurubasavaraja Swamy Purwarga Matada
    Nulgumnalli Manjunathaiah Raghavendra
    Abhishek Ghara
    Ekta Singh
    Nahid Abbas
    Ganesh Sakaram Andhale
    Ganesh Prasad Shenoy
    Pujan Sasmal
    Medicinal Chemistry Research, 2022, 31 : 1401 - 1413
  • [6] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Dhiwar, Prasad Sanjay
    Matada, Gurubasavaraja Swamy Purwarga
    Raghavendra, Nulgumnalli Manjunathaiah
    Ghara, Abhishek
    Singh, Ekta
    Abbas, Nahid
    Andhale, Ganesh Sakaram
    Shenoy, Ganesh Prasad
    Sasmal, Pujan
    MEDICINAL CHEMISTRY RESEARCH, 2022, 31 (09) : 1401 - 1413
  • [7] Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors
    Luo, Min
    Fu, Li-Wu
    AMERICAN JOURNAL OF CANCER RESEARCH, 2014, 4 (06): : 608 - 628
  • [8] HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
    Wang, Shizhen Emily
    Narasanna, Archana
    Perez-Torres, Marianela
    Xiang, Bin
    Wu, Frederick Y.
    Yang, Seungchan
    Carpenter, Graham
    Gazdar, Adi F.
    Muthuswamy, Senthil K.
    Arteaga, Carlos L.
    CANCER CELL, 2006, 10 (01) : 25 - 38
  • [9] Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
    Norma O’Donovan
    Annette T. Byrne
    Aisling E. O’Connor
    Sharon McGee
    William M. Gallagher
    John Crown
    Investigational New Drugs, 2011, 29 : 752 - 759
  • [10] Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
    O'Donovan, Norma
    Byrne, Annette T.
    O'Connor, Aisling E.
    McGee, Sharon
    Gallagher, William M.
    Crown, John
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 752 - 759
12345